Search clinical trials for: rivaroxaban

Total 536 results

Bayer
Janssen Research & Development, LLC

Completed

A Study to Gather Information About Rivaroxaban in Patients in the United Kingdom Who Have Cancer and Thrombosis (OSCAR-UK)

Treatment of Venous Thromboembolism in Cancer Patients

United Kingdom
University of Alberta

Completed

Rivaroxaban in Type 2 Myocardial Infarctions (R2MI)

Type II Myocardial Infarction

Canada
Laval University

Withdrawn

DOAC Versus VKA After Cardiac Surgery (DOAC/VKA)

Anticoagulant-induced Bleeding

Canada
Thomas Kander

Completed

The Effects of Hypothermia and Acidosis on Coagulation During Treatment With Rivaroxaban Measured With ROTEM

Bleeding | Trauma | Hypothermia | Acidosis

Sweden
Portola Pharmaceuticals

Completed

A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects

Bleeding

United States
Portola Pharmaceuticals

Completed

Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 2 of 4)

Healthy Volunteers
Damascus University
Unipharma, HamaPharma, Almujtahed hospital

Completed

Rivaroxaban vs. Warfarin in CVT Treatment (RWCVT)

Cerebral Vein Thrombosis

Syrian Arab Republic
Portola Pharmaceuticals

Completed

A Study in Older Subject to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Rivaroxaban

Bleeding

United States
Hospital Alemão Oswaldo Cruz
Bayer; Hospital Israelita Albert Einstein; Hospital Moinhos de Vento; Brazilian... and other collaborators

Terminated

COVID-19 Antithrombotic Rivaroxaban Evaluation (CARE)

COVID-19

Brazil
Imperial College London

Terminated

Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial. (C-19-ACS)

COVID-19

United Kingdom
Ottawa Heart Institute Research Corporation

Active, not recruiting

The Safety and Efficacy Of Rivaroxaban and Ticagrelor for Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (CAPITAL PCI AF)

Atrial Fibrillation | Acute Coronary Syndrome

Canada
Bayer

Completed

A Study to Learn About Venous Thromboembolism (VTE) Treatment With Rivaroxaban in Japanese Patients Using a Claims Database

Treatment of Venous Thromboembolism

Japan
Fujita Health University

Completed

Rivaroxaban Estimation With Warfarin in Atrial Fibrillation Patients With Coronary Stent Implantation Study (REWRAPS) (REWRAPS)

Coronary Artery Disease | Stroke | Atrial Fibrillation | All Cause Mortality | Fetal Blood Loss | Major Bleeding

Japan
Bayer
Janssen Research & Development, LLC

Completed

Xarelto for Real Life Anticoagulation in Pulmonary Embolism (PE) in China (XAPEC)

Pulmonary Embolism

China
University Hospital, Basel, Switzerland
Swiss Heart Foundation

Completed

Novel Oral Anticoagulants in Stroke Patients (NOACISP)

Ischemic Stroke | Intracranial Hemorrhages

Switzerland
University of British Columbia

Completed

Study of Rivaroxaban for CeREbral Venous Thrombosis (SECRET)

Cerebral Venous Thrombosis

Canada
Bayer
Janssen Research & Development, LLC

Completed

Xarelto on Prevention of Stroke and Non-Central Nervous Systemic Embolism in Renally Impaired Korean Patients With Non-valvular Atrial Fibrillation (XARENAL)

Non-valvular Atrial Fibrillation (NVAF)

Korea, Republic of
Centre Hospitalier Universitaire de Saint Etienne

Completed

Non Inferiority Study of a Reduced Dose of Activated Charcoal on Rivaroxaban Pharmacokinetics. (RICHAR2)

Healthy

France
Bayer
Janssen Research & Development, LLC; Population Health Research Institute

Completed

Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease (COMPASS)

Prevention & Control

Belgium, Finland, France, China, United States, Colombia, Ireland, Philippines, Japan, Hungary, Canada, Germany, Australia, Chile, Czechia, Korea, Republic of, Malaysia, Brazil, Denmark, Israel, Russian Federation, South Africa, Ecu... and more
Center for Innovation and Research Organization

Completed

A Clinical Simulation Study of a Test Material on the Anterior Nares

Colonization, Asymptomatic

United States
University of California, San Francisco
Patient-Centered Outcomes Research Institute; Kaiser Permanente

Completed

Anticoagulation Length of ThErapy and Risk of New Adverse evenTs In Venous thromboEmbolism Study (ALTERNATIVE)

Venous Thromboembolism | Anticoagulants and Bleeding Disorders

United States
Bayer
Janssen Research & Development, LLC

Completed

Special Drug Use Investigation of Xarelto for Venous Thromboembolism (VTE) (JPMS-XAR-VTE)

Venous Thromboembolism

Japan
Bayer
Janssen Research & Development, LLC

Completed

An Observational Study Called H2H-OSCAR-US to Learn More About How Well Rivaroxaban Works and How Safe it is Compared to Apixaban Under Real World Conditions in People in the US With Cancer Who Have Problems Due to Formation of Blood Clots in the Veins (Venous Thromboembolism) (H2H-OSCAR-US)

Cancer | Venous Thromboembolism | Treatment of Venous Thromboembolism in Cancer Patients

Germany
Centre Hospitalier Universitaire de Saint Etienne
Ministry of Health, France

Terminated

Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants (VERDICT)

Renal Insufficiency

France
Population Health Research Institute
Bayer; University of Cape Town

Completed

INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Non-Inferiority (INVICTUS-VKA)

Rheumatic Heart Disease

Botswana, Philippines, Zimbabwe, India, China, Egypt, Ethiopia, Uganda, Brazil, South Africa, Cameroon, Tanzania, Kenya, Zambia, Kazakhstan, Kyrgyzstan, Malawi, Mexico, Mozambique, Nepal, Nigeria, Pakistan, Paraguay, Rwanda, Sudan
Bursa Postgraduate Hospital

Completed

Rivaroxaban - Percutaneous Coronary Intervention

Coronary Artery Disease | Atrial Fibrillation

Turkey
University of Karachi
Center for Bioequivalence Studies and Clinical Research (CBSCR), HEJ Research... and other collaborators

Completed

Bioequivalence of Xaroban 20mg (Rivaroxaban) Tablet and Xarelto 20mg (Rivaroxaban) Tablet Under Fed Conditions (Bioequivalence)

Bioequivalence

Pakistan
Instituto Mexicano del Seguro Social

Completed

Rivaroxaban Plus Aspirin to Manage Recurrent Venous Thromboembolic Events

Venous Thromboembolism | Pulmonary Embolism | Anticoagulant-induced Bleeding | Venous Thromboses

Mexico
Kansas City Heart Rhythm Institute
Kansas City Heart Rhythm Research Foundation

Completed

DOACs for Stroke Prevention Post Ventricular Tachycardia Ablation (STROKE-VT)

Stroke | Ventricular Tachycardia | Premature Ventricular Contraction

United States, India
Doasense GmbH

Active, not recruiting

Pharmacokinetics and Point of Care Testing of Direct Oral Anticoagulants Subjects (PHAPOCU)

Anticoagulant Therapy

Germany
Bayer
Janssen Research & Development, LLC

Completed

Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation (XANTUS)

Atrial Fibrillation

Austria, Czechia, Hungary, Israel, Russian Federation, Slovakia, Slovenia, Germany, United Kingdom, France, Belgium, Canada, Netherlands, Poland, Denmark, Sweden, Portugal, Ireland, Norway, Moldova, Republic of, Ukraine
Assistance Publique - Hôpitaux de Paris

Completed

Xarelto Versus no Treatment for the Prevention of Recurrent Thrombosis in Patients With Chronic Portal Vein Thrombosis. (RIPORT)

Deep Vein Thrombosis | Chronic Portal Vein Thrombosis

France
University Hospital, Brest
Bayer

Completed

Pharmacokinetics of Rivaroxaban After Bariatric Surgery (ABSORB)

Morbid Obesity | Bariatric Surgery

France
Ain Shams University
Misr International University

Completed

Effect of Prophylactic and Therapeutic Anticoagulants in Egyptian Patients With COVID-19

Covid19 | Corona Virus Infection | Hypercoagulability

Egypt
Daiichi Sankyo UK Ltd, a Daiichi Sankyo Company

Completed

Study to Evaluate the Use of Direct Oral Anticoagulants in UK Clinical Practice For Patients With a First Stroke Attributable to Nonvalvular Atrial Fibrillation

Atrial Fibrillation

United Kingdom
Population Health Research Institute
University of Cape Town

Withdrawn

INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Superiority (INVICTUS-ASA)

Rheumatic Heart Disease
University Hospital Tuebingen
Bayer

Withdrawn

Reveal Transition - A Mechanistic Study in Transition / Stabilized Phase of CAD (RevealTrans)

Cardiovascular Diseases

Germany
University of Florida
Janssen Scientific Affairs, LLC

Completed

Pharmacodynamic Effects of Low-dose Rivaroxaban With Antiplatelet Therapies

Coronary Artery Disease | Peripheral Arterial Disease | Atrial Fibrillation

United States
Bayer
Janssen Research & Development, LLC

Completed

Exploring the Efficacy and Safety of Rivaroxaban to Support Elective Percutaneous Coronary Intervention (X-PLORER)

Coronary Artery Disease | Cardiovascular Disease

Belgium, Netherlands
Yuhan Corporation

Completed

BE Study of Two Formulations of Rivaroxaban 2.5 mg in Healthy Subjects

Healthy Volunteer

Korea, Republic of
Bayer
Janssen Research & Development, LLC

Completed

A Study Using Electronic Health Information to Learn About Rivaroxaban Compared to Warfarin in Participants With Non-valvular Atrial Fibrillation (NVAF) and Diabetes (RIVA-DM)

Atrial Fibrillation

United States
University of Sao Paulo General Hospital

Completed

Tooth Extraction in Patients With Atrial Fibrillation in Use of New Oral Anticoagulants

Hemorrhage | Atrial Fibrillation | Periodontal Disease

Brazil
Medical College of Wisconsin
Ohio State University; Versiti

Completed

Post-thrombotic Syndrome & Predictors of Recurrence in Catheter-related Thrombosis

Neoplasms | Venous Thrombosis

United States
Bristol-Myers Squibb

Completed

APIXABAN in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France SNIIRAM Study

Anticoagulation

France
Bristol-Myers Squibb

Completed

Real-World Comparative Observational Study in Non-Valvular Atrial Fibrillation Patients Using Oral Anticoagulants

Atrial Fibrillation
Bayer
Janssen, LP

Completed

Study to Gain Insights in Treatment Patterns and Outcomes in Patients With Atherosclerosis Prescribed to Xarelto in Combination With Acetylsalicylic Acid (XATOA)

Atherosclerosis

Germany, Argentina, Brazil, Canada, Denmark, Israel, Korea, Republic of, Lebanon, Luxembourg, Mexico, Norway, Russian Federation, Slovenia, Sweden, Switzerland, Thailand, United Arab Emirates, United Kingdom
Jing Liu
Bayer

Terminated

Nifedipine GITS and Amlodipine Besylate on Recovery of Blood Pressure Rhythm and Arterial Stiffness (NARRAS)

Hypertension

China
Bayer

Completed

Study to Compare the Effectiveness of Rivaroxaban (Xarelto) Versus Low-molecular-weight Heparin (LMWH) and Phenprocoumon for the Treatment and Secondary Prevention of Venous Thromboembolism in Routine Clinical Practice in Germany

Venous Thromboembolism

Germany
Doasense GmbH
Clinical Research Services, Mannheim, Germany; Institute Medical Statistics... and other collaborators

Completed

In Vitro Diagnostic Test for DOAC in Urine (PADOASU)

Anticoagulant Therapy

Germany
Radboud University Medical Center

Active, not recruiting

Trained Immunity by Dual-pathway Inhibition in Coronary Artery Disease (DUALCAD)

Coronary Artery Disease

Netherlands

Search clinical trials for: rivaroxaban

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Dominican Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations